{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:39:47Z","timestamp":1790566787060,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10792-017-0749-2","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T17:27:33Z","timestamp":1508952453000},"page":"2669-2675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report"],"prefix":"10.1007","volume":"38","author":[{"given":"Morara","family":"Mariachiara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruatta","family":"Celeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foschi","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balducci","family":"Nicole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciardella","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"749_CR1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2013.07.014","volume":"121","author":"SU Shah","year":"2014","unstructured":"Shah SU, Mashayekhi A, Shields CL (2014) Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology 121:352\u2013357","journal-title":"Ophthalmology"},{"issue":"5","key":"749_CR2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.breast.2004.08.019","volume":"14","author":"E Munzone","year":"2005","unstructured":"Munzone E, Nol\u00e8 F, Sanna G et al (2005) Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. Breast 14(5):380\u2013383","journal-title":"Breast"},{"key":"749_CR3","first-page":"2958","volume":"7","author":"F Ciardiello","year":"2001","unstructured":"Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the EGFR pathway for cancer therapy. Clin Cancer Res 7:2958\u20132970","journal-title":"Clin Cancer Res"},{"issue":"6","key":"749_CR4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.survophthal.2011.05.001","volume":"56","author":"CJ Chen","year":"2011","unstructured":"Chen CJ, McCoy AN, Brahmer J (2011) Emerging treatment for choroidal metastasis. Surv Ophthalmol 56(6):511\u2013521","journal-title":"Surv Ophthalmol"},{"key":"749_CR5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s12032-014-0901-z","volume":"31","author":"VN Maturu","year":"2014","unstructured":"Maturu VN, Singh N, Bensal P (2014) Combination of intravitreal Bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systemic review of literature. Med Oncol 31:901","journal-title":"Med Oncol"},{"key":"749_CR6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1146\/annurev.bi.56.070187.004313","volume":"56","author":"G Carpenter","year":"1987","unstructured":"Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56:881\u2013914","journal-title":"Annu Rev Biochem"},{"issue":"S1","key":"749_CR7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/onc.2009.197","volume":"28","author":"T John","year":"2009","unstructured":"John T, Liu G, Tsao M-S (2009) Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for prediction of response to tyrosine kinase inhibitors. Oncogene 28(S1):S14\u2013S23","journal-title":"Oncogene"},{"key":"749_CR8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.survophthal.2011.05.001","volume":"56","author":"CJ Chen","year":"2011","unstructured":"Chen CJ, McCoy AN, Brahmer J et al (2011) Emerging treatment for choroidal metastases. Surv Ophthalmol 56:511\u2013521","journal-title":"Surv Ophthalmol"},{"key":"749_CR9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/ICB.0b013e3181e180e6","volume":"4","author":"AB Daniels","year":"2010","unstructured":"Daniels AB, Miller ML, Kotecha A et al (2010) Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib. Retin Cases Brief Rep 4:390\u2013393","journal-title":"Retin Cases Brief Rep"},{"key":"749_CR10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0091-3057(95)02075-6","volume":"53","author":"AH Jerram","year":"1996","unstructured":"Jerram AH, Smith PF, Darlington CL (1996) A dose-response analysis of the behavioral effects of (+)MK-801 in guinea pig: comparison with CPP. Pharmacol Biochem Behav 53:799\u2013807","journal-title":"Pharmacol Biochem Behav"},{"key":"749_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0974-620X.137159","volume":"7","author":"X Ye","year":"2014","unstructured":"Ye X, Kaliki S, Shields CL (2014) Rapid regression of choroidal metastasis from lung cancer using Erlotinib (Tarceva). Oman J Ophthalmol 7:75\u201377","journal-title":"Oman J Ophthalmol"},{"key":"749_CR12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/0970-2113.135767","volume":"31","author":"C Desai","year":"2014","unstructured":"Desai C, Mehta A, Mishra D (2014) Usage patterns of biomarkers in non-small-cell lung cancer patients in India: findings from a systematic review and survey. Lung India 31:249\u2013259","journal-title":"Lung India"},{"key":"749_CR13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0973-1482.113379","volume":"9","author":"T Ovcaricek","year":"2013","unstructured":"Ovcaricek T, Cufer T, Kern I (2013) Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications. J Cancer Res Ther 9:261\u2013266","journal-title":"J Cancer Res Ther"},{"key":"749_CR14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S (2009) Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"749_CR15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046\u20131061","journal-title":"Cancer Discov"},{"key":"749_CR16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","volume":"11","author":"Y Kim","year":"2012","unstructured":"Kim Y, Ko J, Cui Z (2012) The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 11:784\u2013791","journal-title":"Mol Cancer Ther"},{"key":"749_CR17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"JA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne JA, Yang JC, Kim DW (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689\u20131699","journal-title":"N Engl J Med"},{"key":"749_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2017.02.017","volume":"321","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Cao WX, Su MX et al (2017) Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lug cancer cells. Toxicol Appl Pharmacol 321:18\u201326","journal-title":"Toxicol Appl Pharmacol"},{"key":"749_CR19","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.jcjo.2016.09.010","volume":"52","author":"D Maskell","year":"2017","unstructured":"Maskell D, Geropantas K, Kouroupis M (2017) Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs? Can J Ophthalmol 52:e22\u2013e25","journal-title":"Can J Ophthalmol"},{"key":"749_CR20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2147\/OTT.S100650","volume":"10","author":"N Saad","year":"2017","unstructured":"Saad N, Poudel A, Basnet A et al (2017) Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). Onco Targets Ther 10:1757\u20131766","journal-title":"Onco Targets Ther"},{"key":"749_CR21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000448114","volume":"3","author":"AG Nair","year":"2017","unstructured":"Nair AG, Asnani HT, Mehta VC et al (2017) Tyrosine kinase inhibitors in the treatment of choroidal metastases from non-small-cell lung cancer: a case report and review of literature. Ocul Oncol Patol 3:28\u201333","journal-title":"Ocul Oncol Patol"},{"issue":"7","key":"749_CR22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ophtha.2010.12.018","volume":"118","author":"CM Patino","year":"2011","unstructured":"Patino CM, Varma R, Azen SP (2011) The impact of change in visual field on health-related quality of life: the Los Angeles Latino eye study. Ophthalmology 118(7):1310\u20131317","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-017-0749-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0749-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0749-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T11:06:06Z","timestamp":1659697566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-017-0749-2"}},"subtitle":["Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor"],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s10792-017-0749-2","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]}}}